GLP-1 Price Philippines 2026

One structural note before you use this table. Retatrutide has no pharmacy route in this country and no branded product anywhere, because it is still in trials. It appears in the index because it is priced and available as a research compound here, not because you can compare it like for like against a registered pen. Everything else in the table has both a pharmacy and a research-grade existence, which is what makes the class unusual and what makes price comparison meaningful in the first place.

Because every pen in this class covers four weekly doses, the pen price is effectively the monthly price at a steady maintenance dose. That makes the pharmacy side easy to compare, and it kills a claim this site used to make. Within the semaglutide molecule, moving from the Ozempic label to the Wegovy label does not double the cost per dose: at a matched 1mg dose Wegovy is ₱9,900 against ₱8,734 for Ozempic, about thirteen percent more. The premium only shows up at the tiers Ozempic does not offer here, and even the top Wegovy pen at 2.4mg is ₱12,650.

The steep ladder in this class is Mounjaro, not Wegovy. Tirzepatide pricing is markedly non-linear: ₱13,550 at 5mg, then ₱20,350 at 7.5mg and ₱22,950 at 10mg, then a flat ₱29,900 for both 12.5mg and 15mg. Someone titrating from 5mg up to 10mg sees the monthly bill grow by about seventy percent while the dose doubles, and the two top strengths cost the same, which is the one place on this shelf where a higher dose is not a higher bill.

Stock, not price, is the variable that actually costs people money here. Mounjaro strengths have been restricted to click and collect, Ozempic has been rationed at branch level with limits reported at two pens per dosage per month, and a price on a pen nobody has in stock is not a price. Confirm availability in the same call as the quote, and take the prescribing question to a licensed Philippine physician before you shop on price at all.

Cost per dose is the only comparison that survives a change of dose tier, and it is the number I would run before making any decision in this class. It exposes something the pen prices hide, and it does not point the same way for both molecules. Within semaglutide the multiplier compresses as the dose rises, from roughly three times at the 0.5mg tier to roughly two at 1mg and at 2.4mg, because a research vial is priced by total milligrams while a pen is priced by the box regardless of what you dial in. Within tirzepatide it does the opposite: the Mounjaro price ladder climbs faster than the dose does, so the gap widens from about three and a half times at 5mg to about four times at 10mg.

What that means practically is that branded semaglutide is least bad, financially, for someone running a high maintenance dose, and worst for someone on a low starter dose paying full pen price for a quarter of the drug. For tirzepatide the pattern inverts: the 5mg Mounjaro pen is the efficient end of that brand and the top strengths are the expensive end. Worth stating plainly, because this site got it wrong before August 2026: the gap between branded pens and research vials in this market is roughly two to four times, not the five or six times commonly quoted.

GLP-1 protocols are not three-month projects, so the annual column is the honest one. At the top of that table a year on Mounjaro at 15mg runs past six thousand dollars out of pocket. A year on branded semaglutide, whichever label, sits between roughly sixteen hundred and twenty-seven hundred, which is a great deal less than the figures this site carried before August 2026. At the bottom a year of research-grade semaglutide sits under a thousand. In a market where PhilHealth does not cover this class for weight loss and HMO coverage has applied only to the diabetes indication with pre-authorization, essentially all of that is your own money.

That arithmetic, not any argument about molecules, is why a large share of self-directed protocols in this country run on vials. The honest version of that comparison is narrower than the one usually sold, though: against branded semaglutide the vial route saves roughly two to three times, not six. It is also why I insist on pricing the research route honestly rather than flattering it, which is the next section.